The global diabetic retinopathy market size was valued at USD 9.78 billion in 2025 and is projected to grow from USD 10.47 billion in 2026 to USD 18.13 billion by 2034 at a CAGR of 7.1% during the forecast period 2026-2034. North America dominated the diabetic retinopathy market with a market share of 38.5% in 2025.
Diabetic retinopathy is a diabetes-related illness that impacts the eyes. The condition results from harm to the blood vessels in the light-sensitive tissue located in the rear of the eye, referred to as the retina. Initially, diabetic retinopathy may be asymptomatic or only result in minor vision issues. However, in the long run, it can result in blindness. Diabetic retinopathy can occur in individuals with either type 1 or type 2 diabetes. The longer duration of diabetes and poor blood sugar control increases the likelihood of developing this eye problem.
Download a Free Sample To learn more about this report,
The growing prevalence of diabetes worldwide is significantly increasing the demand for diabetic retinopathy screening, diagnosis, and treatment services. Sedentary lifestyles, unhealthy dietary habits, obesity, and an ageing population have contributed to a steady rise in diabetes cases, resulting in a larger patient pool at risk of vision-threatening complications. As diabetic retinopathy often progresses without noticeable symptoms in its early stages, healthcare providers are placing greater emphasis on routine retinal examinations for early detection and timely intervention. Governments and healthcare organisations are also expanding diabetes awareness programmes and preventive eye care initiatives to reduce avoidable blindness. The growing adoption of regular screening programmes is expected to improve diagnosis rates and increase demand for advanced ophthalmic imaging devices and treatment options over the coming years.
Continuous technological advancements are reshaping the diabetic retinopathy market by improving the accuracy of diagnosis and expanding treatment options. Innovations such as artificial intelligence (AI)-assisted retinal screening, ultra-widefield retinal imaging, optical coherence tomography (OCT), and longer-lasting anti-VEGF therapies are enabling earlier disease detection and more personalised treatment. These technologies help clinicians identify retinal damage at earlier stages while reducing diagnostic time and improving patient outcomes. In addition, healthcare providers are increasingly integrating digital ophthalmology solutions into routine diabetes management, particularly in remote and underserved regions where access to specialists is limited. As healthcare systems continue to invest in advanced ophthalmic technologies, the adoption of innovative diagnostic and therapeutic solutions is expected to accelerate worldwide.
Rising Global Diabetes Prevalence Drives Demand for Diabetic Retinopathy Diagnosis and Treatment
The increasing prevalence of diabetes is one of the primary factors driving the growth of the diabetic retinopathy market. Sedentary lifestyles, unhealthy diets, obesity, and reduced physical activity have contributed to a steady rise in diabetes cases across both developed and developing countries. Since diabetic retinopathy is one of the most common complications of diabetes, the expanding diabetic population is significantly increasing the demand for early diagnosis, routine retinal screening, and effective treatment solutions. Healthcare providers are also strengthening diabetes management programs to reduce vision loss through timely intervention. As the number of people living with diabetes continues to grow, demand for advanced retinal imaging systems, anti-VEGF therapies, and laser treatments is expected to rise steadily during the forecast period.
Growing Ageing Population Increases the Risk of Diabetic Retinopathy
The rapidly expanding ageing population is significantly contributing to the growth of the diabetic retinopathy market. Older adults are more susceptible to chronic diseases such as type 2 diabetes, making them more vulnerable to diabetes-related eye disorders, including diabetic retinopathy. As life expectancy continues to improve globally, healthcare systems are witnessing a growing demand for ophthalmic examinations, retinal imaging, and long-term disease management. Governments and healthcare providers are also investing in preventive eye care services to address the increasing burden of age-related vision disorders. This demographic shift is expected to create sustained demand for advanced diagnostic technologies and effective treatment options for diabetic retinopathy in the coming years.
Limited Awareness and Low Screening Rates Delay Early Diagnosis of Diabetic Retinopathy
Limited awareness of diabetic retinopathy remains a major challenge for the market, particularly in low- and middle-income countries where access to diabetes education and routine eye care is often limited. Many people living with diabetes are unaware that the disease can damage the retina long before noticeable vision problems develop. As a result, patients frequently delay comprehensive eye examinations until the condition has progressed to an advanced stage, reducing the effectiveness of available treatments. In addition, inadequate awareness among primary healthcare providers and unequal access to ophthalmology specialists can lead to delayed referrals and missed diagnoses. These factors increase the risk of irreversible vision loss while limiting the adoption of diagnostic imaging systems and treatment procedures. Strengthening public awareness campaigns, expanding diabetic eye screening programmes, and improving collaboration between diabetes specialists and ophthalmologists are essential to overcoming this restraint and improving patient outcomes.
Advancements in AI-Powered Retinal Imaging and Digital Eye Care Create New Growth Opportunities
Continuous advancements in diagnostic imaging technologies and treatment modalities are creating significant growth opportunities in the diabetic retinopathy market. The integration of artificial intelligence (AI), machine learning (ML), cloud computing, and teleophthalmology is improving the speed and accuracy of retinal disease detection while enabling earlier intervention. AI-assisted retinal screening solutions can analyse retinal images within minutes, helping healthcare providers identify diabetic retinopathy before symptoms become severe. These technologies also support remote screening programmes, making quality eye care more accessible in underserved and rural communities. At the same time, improvements in optical coherence tomography (OCT), ultra-widefield imaging, and digital health platforms are enhancing disease monitoring and treatment planning. As healthcare systems continue to invest in digital ophthalmology and preventive eye care, the adoption of these advanced technologies is expected to accelerate worldwide.
High Cost of Advanced Diagnostic Technologies and Limited Access to Specialist Eye Care Challenge Market Growth
The high cost of advanced retinal imaging systems and limited access to specialist eye care remain key challenges for the diabetic retinopathy market. Technologies such as optical coherence tomography (OCT), ultra-widefield retinal imaging, and AI-powered screening platforms require significant investment, making them less accessible for smaller hospitals and healthcare facilities, particularly in low- and middle-income countries. In addition, many rural and underserved regions face shortages of ophthalmologists and retinal specialists, resulting in delayed diagnosis and treatment. Although digital health and teleophthalmology are helping to bridge this gap, infrastructure limitations and inadequate reimbursement policies continue to slow widespread adoption. Addressing these challenges will require increased government funding, improved healthcare infrastructure, and broader deployment of affordable screening programmes to ensure timely access to diabetic eye care services.
Request Customizationto receive a tailored report.
Non-proliferative Diabetic Retinopathy Dominated the Market with a 57.3% Share in 2025
The non-proliferative diabetic retinopathy (NPDR) segment accounted for the largest share of the diabetic retinopathy market in 2025, capturing 57.3% of the global market. NPDR is the earliest and most common stage of diabetic retinopathy, making it the condition most frequently diagnosed during routine diabetic eye examinations
Anti-VEGF Drugs are Expected to Register the Highest CAGR of 8.71% During 2026–2034
The anti-VEGF drug segment is projected to witness the fastest growth during the forecast period, expanding at a CAGR of 8.71% from 2026 to 2034. Anti-VEGF therapies have become the preferred treatment for diabetic retinopathy and diabetic macular edema due to their ability to reduce retinal swelling, control abnormal blood vessel growth, and preserve vision
Speak to an Analystto discuss market opportunities.
North America dominated the diabetic retinopathy market with a 38.5% share, valued at USD 3.77 billion in 2025, and is projected to grow at a CAGR of 7.84% during the forecast period. The region's leadership is supported by the high prevalence of diabetes, advanced healthcare infrastructure, and widespread availability of retinal screening and treatment services.
The United States accounted for the largest share of the North American market, reaching USD 3.02 billion in 2025. The country benefits from a large diabetic population, extensive access to specialised ophthalmic care, and the rapid adoption of AI-assisted retinal imaging technologies.
Canada's diabetic retinopathy market was valued at USD 0.75 billion in 2025. Market growth is driven by rising diabetes prevalence, government-supported vision care initiatives, and improved access to retinal screening services.
Europe accounted for 27.4% of the global diabetic retinopathy market, valued at USD 2.68 billion in 2025, and is expected to grow at a CAGR of 7.46% during the forecast period. Growth is supported by increasing awareness of diabetic eye diseases, strong public healthcare systems, and widespread implementation of national diabetic screening programmes.
Germany's diabetic retinopathy market reached USD 0.83 billion in 2025. The country's advanced healthcare infrastructure, high adoption of retinal imaging technologies, and strong presence of ophthalmology specialists continue to support market growth. Increasing healthcare expenditure and government initiatives promoting early diabetic eye examinations are further driving demand for diagnostic and treatment solutions.
The United Kingdom recorded a market value of USD 0.61 billion in 2025. Growth is supported by the National Health Service (NHS) Diabetic Eye Screening Programme, which promotes regular retinal examinations for individuals with diabetes.
Asia-Pacific held a 23.6% share of the global diabetic retinopathy market, reaching USD 2.31 billion in 2025, and is projected to register the fastest CAGR of 9.38% during the forecast period. The region is experiencing rapid market expansion due to the rising prevalence of diabetes, growing ageing population, improving healthcare infrastructure, and increasing government investments in preventive healthcare.
Japan's diabetic retinopathy market was valued at USD 0.64 billion in 2025. The country's rapidly ageing population, advanced healthcare system, and strong adoption of innovative ophthalmic technologies continue to drive market growth. Increasing demand for early diagnosis and effective treatment options is encouraging hospitals and specialty eye clinics to adopt advanced retinal imaging and AI-supported screening solutions.
China accounted for the largest share of the Asia-Pacific market, reaching USD 1.08 billion in 2025. Market growth is driven by the country's large diabetic population, expanding healthcare infrastructure, and increasing government efforts to improve chronic disease management.
The Middle East and Africa accounted for 4.4% of the global diabetic retinopathy market, valued at USD 0.43 billion in 2025, and is expected to grow at a CAGR of 7.69% during the forecast period. Market growth is supported by increasing diabetes prevalence, improving healthcare infrastructure, and rising investments in specialised ophthalmic care.
The United Arab Emirates diabetic retinopathy market reached USD 0.17 billion in 2025. Rising diabetes rates, strong healthcare investments, and increasing adoption of AI-powered diagnostic technologies are driving market expansion.
Latin America held a 6.1% share of the global diabetic retinopathy market, reaching USD 0.60 billion in 2025, and is projected to grow at a CAGR of 8.21% during the forecast period. Increasing diabetes prevalence, improving healthcare access, and expanding public health initiatives are supporting market growth across the region.
Brazil accounted for the largest share of the Latin American market, with a value of USD 0.31 billion in 2025. Market growth is supported by the country's large diabetic population, improving access to ophthalmic care, and expanding public healthcare programmes focused on chronic disease management.
Unlock Regional Insightsto access country-level data, & regional trends.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a Healthcare Lead with over 7 years of industry experience, specializing in Healthcare IT. She provides comprehensive market insights on digital health, electronic medical records, telehealth, and healthcare analytics. Debashree’s research supports organizations in adopting technology-driven healthcare solutions, improving patient care, and achieving operational efficiency in a rapidly transforming healthcare ecosystem.
We are featured on:
sales@straitsresearch.com